Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Boston Scientific Corporation
BSX
NYSE·Healthcare·Medical - Devices·Mkt cap $64.0B
$45.14
▲ +4.83%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$42.25 - $109.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 58.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive medical device patent portfolio
- Global research and development capabilities
- Diversified product lines across multiple medical specialties
- Strong regulatory compliance and clinical validation
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Aging global population
Value
Attractively priced below Medical Devices peer average
Momentum
Falling
-31.5% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying BSX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 21, 2026
APR 22, 2026
Reported EPS of $0.80 vs $0.79 consensus (+1.5% surprise). Revenue of $5.2B vs $5.2B expected (+0.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+1.5%
Next: Apr 21, 2026
Revenue trend · last 8Q
—
—
+22%
+21%
+23%
+20%
+16%
+12%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$4.1B
$4.2B
$4.6B
$4.7B
$5.1B
$5.1B
$5.3B
$5.2B
Margins · last 8Q
Gross
69.4%
Operating
20.6%
Profit
25.7%
Wall Street consensus
24 analysts · 92% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
92%
Hold
8%
Sell
0%
Median Price Target
$77.50
▲ +71.7% vs $45.14
Latest: Piper Sandler · Jun 12, 2026
15 analysts covering